The closing price of Cellebrite DI Ltd (NASDAQ: CLBT) was $11.45 for the day, down -3.54% from the previous closing price of $11.87. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 1292352 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of CLBT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.60 and its Current Ratio is at 1.64. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.27.
On February 16, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $9 to $12.
On July 19, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $11.Craig Hallum initiated its Buy rating on July 19, 2023, with a $11 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 2.35B and an Enterprise Value of 2.06B. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.23 while its Price-to-Book (P/B) ratio in mrq is 68.02. Its current Enterprise Value per Revenue stands at 6.34 whereas that against EBITDA is -31.49.
Stock Price History:
Over the past 52 weeks, CLBT has reached a high of $12.50, while it has fallen to a 52-week low of $5.22. The 50-Day Moving Average of the stock is 10.58, while the 200-Day Moving Average is calculated to be 8.33.
Shares Statistics:
CLBT traded an average of 946.33K shares per day over the past three months and 1.11M shares per day over the past ten days. A total of 203.23M shares are outstanding, with a floating share count of 55.50M. Insiders hold about 72.96% of the company’s shares, while institutions hold 25.48% stake in the company. Shares short for CLBT as of Feb 29, 2024 were 2.35M with a Short Ratio of 2.77, compared to 2.66M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.19% and a Short% of Float of 3.94%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of $0.06 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.05, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.34 and $0.29 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is $0.39, with 5 analysts recommending between $0.43 and $0.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $88M to a low estimate of $84.02M. As of the current estimate, Cellebrite DI Ltd’s year-ago sales were $71.23M, an estimated increase of 20.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $90.28M, an increase of 17.70% less than the figure of $20.20% in the same quarter last year. There is a high estimate of $91.12M for the next quarter, whereas the lowest estimate is $89.11M.
A total of 7 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $380M, while the lowest revenue estimate was $375.02M, resulting in an average revenue estimate of $376.82M. In the same quarter a year ago, actual revenue was $325.11M, up 15.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $449.06M in the next fiscal year. The high estimate is $467M and the low estimate is $433.2M. The average revenue growth estimate for next year is up 19.20% from the average revenue estimate for this year.
